ArticleCancer immunology, immunotherapy : CII2025
Suppression of STK11 induces expansion of polymorphonuclear myeloid-derived suppressive cells and activation of immune signaling in breast cancer.
Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The tumor microenvironment in breast cancer is typically immunosuppressive. Combined neoadjuvant chemotherapy and immunotherapy is the standard of care for high-risk, triple-negative breast cancer patients, but it is not routinely applied to other breast cancer subtypes. Somatic mutation of STK11 (serine/threonine kinase 11), a tumor suppressor, occurs in the MSK-IMPACT platform in 1.9% of 3116 breast cases. A potential link between inactivation of STK11 and immune response regulation has been suggested in breast cancer, but the impact of STK11 suppression on tumor-immune interactions remains under investigation. In this study, we established Stk11-knockout (Stk11-KO) mouse breast cancer cell lines, performed RNA sequencing and cytokine array analysis to assess alterations in gene expression and cytokine profiles. Our results revealed significant enrichment of several immune-related pathways and a marked increase in C-X-C motif chemokine ligand 1 (Cxcl1) expression in response to Stk11 knockout. Moreover, analysis of breast cancer patient samples showed an inverse association between the plasma CXCL1 levels and STK11 expression. To evaluate the in vivo effects of STK11 loss, we established an orthotopic breast cancer model in immunocompetent female mice. Tumors derived from Stk11-KO mouse breast cancer cells demonstrated greater tumorigenicity. In addition, mice-bearing Stk11-KO tumors exhibited elevated levels of circulating polymorphonuclear myeloid-derived suppressive cells. In summary, STK11 suppression enhances immune-related pathways and promotes Cxcl1 expression, correlating with the expansion of immunosuppressive MDSC populations. Our findings suggest that targeting STK11-associated immunosuppressive mechanisms may provide a novel therapeutic option for STK11-deficient breast cancer patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.